Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
Public ClinicalTrials.gov record NCT01009593. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Randomized Phase 3 Study of the Efficacy and Tolerability of Linifanib (ABT-869) Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
Study identification
- NCT ID
- NCT01009593
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Abbott
- Industry
- Enrollment
- 1,035 participants
Conditions and interventions
Conditions
- Hepatocellular Carcinoma Non-resectable
- Hepatocellular Carcinoma Recurrent
- Carcinoma, Hepatocellular
- Liver Diseases
- Neoplasms by Histologic Type
- Digestive System Neoplasms
- Carcinoma
- Liver Neoplasms
- Neoplasms
- Neoplasms by Site
- Digestive System Diseases
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
Interventions
- ABT-869 Drug
- Sorafenib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2009
- Primary completion
- Jun 30, 2012
- Completion
- Jun 30, 2012
- Last update posted
- Sep 9, 2012
2010 – 2012
United States locations
- U.S. sites
- 13
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site Reference ID/Investigator# 23247 | Beverly Hills | California | 90211-1850 | — |
| Site Reference ID/Investigator# 23608 | LaVerne | California | 91750 | — |
| Site Reference ID/Investigator# 23852 | Orange | California | 92868 | — |
| Site Reference ID/Investigator# 40162 | Orange | California | 92868 | — |
| Site Reference ID/Investigator# 23254 | Newark | Delaware | 19713 | — |
| Site Reference ID/Investigator# 23253 | Gainesville | Georgia | 30505 | — |
| Site Reference ID/Investigator# 23609 | Honolulu | Hawaii | 96813 | — |
| Site Reference ID/Investigator# 24848 | Honolulu | Hawaii | 96819 | — |
| Site Reference ID/Investigator# 23250 | Louisville | Kentucky | 40202 | — |
| Site Reference ID/Investigator# 23257 | St Louis | Missouri | 63104 | — |
| Site Reference ID/Investigator# 23603 | Las Vegas | Nevada | 89135 | — |
| Site Reference ID/Investigator# 23244 | Durham | North Carolina | 27710 | — |
| Site Reference ID/Investigator# 23252 | Portland | Oregon | 97213 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 150 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01009593, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 9, 2012 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01009593 live on ClinicalTrials.gov.